Tear flow is essential for ocular surface homeostasis, maintained through interactions among the secretory and neurovascular systems, with the meibomian glands, lacrimal gland, goblet cells, conjunctiva, and their vascular and neural networks working together to sustain a stable tear film1,2. This balance relies on the dynamic interplay between tear production and drainage, which directly affects the overall tear turnover rate (TTR)3. A reduced TTR can exacerbate dry eye symptoms by leading to the accumulation of inflammatory mediators on the ocular surface, resulting in what we term Ocular Surface Toxic Soup Syndrome (OSTSS). Reduced TTR is suspected to contribute to dry eye, as symptomatic patients typically have lower tear turnover rates compared to asymptomatic controls4. Tear production and turnover rates likely influence the cytokine environment of the ocular surface, both by delivering cytokines through the tear fluid and by removing those accumulated on the ocular surface5. The dysfunction of the nasolacrimal system, which impairs tear drainage and absorption of tear fluid components, may contribute to the development of OSTSS by allowing inflammatory mediators to accumulate on the ocular surface, potentially triggering abnormal immune responses and exacerbating dry eye pathology6,7.
Punctal plugs have long been a cornerstone in managing dry eye disease associated with aqueous tear deficiency by blocking tear drainage to enhance tear retention on the ocular surface8,9. However, the effectiveness of punctal occlusion has been questioned recently10. Lacrimal irrigation, or nasolacrimal lavage, on the other hand, offers a potential alternative treatment to alleviate dry eye symptoms in cases of suspected OSTSS. In this report, we present a case in which nasolacrimal lavage provided significant relief for a patient with mixed etiologies, demonstrating its versatility as a treatment option.
Consent for nasolacrimal lavage is similar to consent for probe and irrigation, with the primary difference being that nasolacrimal lavage is an off-label, therapeutic treatment for keratoconjunctivitis sicca and allergic conjunctivitis, whereas probe and irrigation is considered a diagnostic procedure to determine the cause of epiphora. Patients must be informed of the off-label nature of this treatment.
The goal of nasolacrimal lavage is to improve tear drainage through the nasolacrimal system to promote tear turnover and clear the lacrimal sac. There are no direct alternatives that accomplish the same goal.
Nasolacrimal lavage carries minimal risk. When performed correctly, and in the absence of nasolacrimal duct obstruction, patients will experience saline drainage either into the back of the throat (with the head tilted back) or into the nose (with the head tilted forward). Mild irritation may occur around the puncta or at the punctal opening. Additionally, there is a slight risk of unintentional contact with the eyelid or globe from the blunt cannula.
When in the setting of epiphora and clinically appropriate, nasolacrimal lavage is a procedure generally covered by insurance under the description of probe and irrigation.
A 73-year-old Black woman presented with complaints of intermittent, yet severe, itchiness medially and mild grittiness in both eyes. The patient's ocular medications included cyclosporine 0.05%, twice daily in both eyes; preservative-free artificial tears as needed in both eyes; alcaftadine 0.25%, once daily in both eyes; and eyelid wipes once daily. She had previously used tobramycin 0.3% and dexamethasone 0.1% four times daily for 10 days, which provided effective symptom relief, but her symptoms recurred upon discontinuation. Her medical history was notable for bilateral keratoconjunctivitis, bilateral meibomian gland dysfunction, and squamous blepharitis of the upper and lower eyelids in both eyes. Ocular surgical history included barrier laser retinopexy in the right eye for a retinal tear, performed 7 months prior. Systemic medications included atorvastatin for hyperlipidemia and a daily inhalation of fluticasone furoate 200 µg/umeclidinium 62.5 µg/vilanterol 25 µg for chronic obstructive pulmonary disease (COPD).
On ocular surface examination, there was trace inferior corneal staining in both eyes, 1+ bulbar conjunctival injection in both eyes, 1+ papillary reaction of the palpebral conjunctiva in both lower eyelids, mild conjunctivochalasis, 1+ blepharitis of both upper eyelids, and 3+ meibomian gland dysfunction with thickened secretions. Mild lower eyelid laxity was also noted in both eyes. Schimer's I score was 17 mm in the right eye and 14 mm in the left eye.
The patient reported pruritus in the inner canthus of both eyes, where tears drain from the ocular surface into the nasolacrimal duct system through the puncta. Additionally, there was conjunctival injection at the nasal aspect of the bulbar conjunctiva, where tears accumulate before draining from the ocular surface. These findings are consistent with ocular surface tear dysfunction syndrome (OSTSS), which is associated with the accumulation of allergen particulates and inflammatory mediators. Given this, nasolacrimal lavage was performed at the lower puncta of both eyes as an off-label therapeutic intervention to facilitate proper tear drainage and reduce the buildup of allergens and inflammatory mediators in the inner canthus.